The effect of comorbidities on the choice of tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of TKIs. This review article examines the m...

Full description

Saved in:
Bibliographic Details
Published in:International journal of hematologic oncology 2022-03, Vol.11 (1), p.IJH38-IJH38
Main Authors: Saydam, Guray, Ali, Ridvan, Demir, Ahmet Muzaffer, Eskazan, Ahmet Emre, Guvenc, Birol, Haznedaroglu, Ibrahim Celalettin, Ozcan, Mehmet Ali, Salim, Ozan, Sonmez, Mehmet, Tuglular, Ayse Tulin, Turgut, Mehmet, Unal, Ali, Aver, Birkan, Bozkurt, Sirac, Ozdengulsun, Begum, Ilhan, Osman
Format: Article
Language:English
Subjects:
adverse event
chronic myeloid leukemia
comorbidity
drug toxicity
interactions (drug–drug)
Review
safety
tolerability
tyrosine kinase inhibitor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have similar efficacies but different safety profiles. Therefore, the choice of patient-specific treatments is driven by factors such as tolerability and adverse event profile of TKIs. This review article examines the most up-to-date data and provides practical recommendations for clinical approaches. Nilotinib and ponatinib should be avoided in patients with cardiovascular risk factors, dasatinib in patients with lung damage and bosutinib and nilotinib in patients with liver disease. Considering that certain comorbidities predispose some patients to developing severe adverse events when receiving TKIs, the first- and second-line treatment of chronic myeloid leukemia should be tailored to each patient’s individual condition.
ISSN:2045-1393
2045-1407
DOI:10.2217/ijh-2021-0010